Infinium Pharmachem
INFINIUM NSE
Infinium Pharmachem
HealthcareNSE: INFINIUM Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹405 Cr
Volatility
Moderate
P/E Ratio
30.1
EBITDA
₹21.56 Cr
Return on Equity
6.28%
Debt to Equity
0
Book Value
₹77.68
52W High
₹285.5
52W Low
₹189.4
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Promoter holding has increased by 5.00% over last quarter.
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 14.0% over last 3 years.
Growth Rate
Revenue Growth
20.17% higher than
3Y
Net Income Growth
80.9% higher than
3Y
Cash Flow Change
-123% higher than
3Y
ROE
-67.12% lower than
3Y
ROCE
-55.79% higher than
3Y
EBITDA Margin (Avg.)
-4.26% higher than
3Y
Quarterly Results
| Particulars | Sep 2022 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 79 | 61 | 74 | 83 | 73 | 84 | 106 |
| Expenses | 71 | 51 | 66 | 75 | 65 | 74 | 94 |
| Operating Profit | 9 | 10 | 8 | 8 | 8 | 10 | 11 |
| OPM % | 11% | 17% | 11% | 10% | 11% | 12% | 11% |
| Other Income | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
| Depreciation | 0 | 1 | 1 | 2 | 2 | 2 | 2 |
| PBT | 8 | 8 | 7 | 6 | 5 | 8 | 10 |
| Tax % | 22% | 24% | 24% | 25% | 41% | 22% | 19% |
| Net Profit | 6 | 6 | 5 | 5 | 3 | 7 | 8 |
| EPS in Rs | 5.4 | 4.46 | 3.66 | 3.17 | 2.4 | 3.59 | 4.2 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 39 | 71 | 99 | 114 | 136 | 156 | 190 |
| Expenses | 36 | 66 | 89 | 98 | 117 | 136 | 168 |
| Operating Profit | 2 | 5 | 10 | 16 | 19 | 19 | 22 |
| OPM % | 6% | 7% | 10% | 14% | 14% | 12% | 11% |
| Other Income | 1 | 1 | 1 | 1 | 2 | -1 | 2 |
| Interest | 1 | 1 | 2 | 3 | 2 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3 | 3 |
| PBT | 1 | 4 | 9 | 13 | 15 | 12 | 18 |
| Tax % | 30% | 28% | 23% | 24% | 24% | 32% | 20% |
| Net Profit | 1 | 3 | 7 | 10 | 12 | 8 | 14 |
| EPS in Rs | 4.65 | 13.6 | 30.55 | 9.3 | 8.12 | 5.23 | 7.8 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 94 | 105 |
| Borrowings | 9 | 11 | 23 | 29 | 11 | 52 | 0 |
| Other Liabilities | 9 | 17 | 23 | 19 | 15 | 37 | 54 |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
| Fixed Assets | 4 | 5 | 4 | 19 | 20 | 24 | 23 |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29 | 29 |
| Other Assets | 18 | 26 | 46 | 52 | 66 | 144 | 114 |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 3 | 7 | 12 | 9 | -13 | -29 | 34 |
| Investing | -1 | -5 | -7 | -5 | -4 | -27 | -7 |
| Financing | -1 | -1 | -2 | -3 | 23 | 79 | -32 |
| Net Cash Flow | 1 | 1 | 3 | 1 | 6 | 23 | -5 |
| Free Cash Flow | 2 | 2 | 7 | 1 | -17 | -38 | 24 |
| CFO/OP | 137 | 168 | 137 | 73 | -51 | -131 | 174 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 59 | 57 | 49 | 55 | 79 | 61 |
| Inventory Days | 84 | 62 | 78 | 89 | 87 | 137 | 96 |
| Days Payable | 82 | 79 | 56 | 31 | 16 | 38 | 10 |
| Cash Conversion Cycle | 76 | 43 | 78 | 108 | 126 | 178 | 146 |
| Working Capital Days | 46 | 12 | 25 | 27 | 96 | 97 | 99 |
| ROCE % | — | 32% | 38% | 36% | 28% | 15% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Infinium Pharmachem insights
57 extracted metrics + investor summaries across FY20–FY26.
Documents
1
Analysts/Institutional Investor Meet/Con. Call Updates
27 Aug - Infinium Pharmachem schedules Group Institutional Investor meeting and site visit on 3 September 2026 in Anand. 27 Aug - Infinium Pharmachem schedules Group Institutional Investor meeting and site visit on 3 September 2026 in Anand.
2
Copy of Newspaper Publication
26 Aug - Newspaper advertisements published for Infinium Pharmachem's postal ballot notice on August 26, 2026. 26 Aug - Newspaper advertisements published for Infinium Pharmachem's postal ballot notice on August 26, 2026.
3
Record Date
26 Aug - AGM scheduled for 17 September 2026; record date fixed as 10 September 2026 for remote e-voting. 26 Aug - AGM scheduled for 17 September 2026; record date fixed as 10 September 2026 for remote e-voting.
4
Copy of Newspaper Publication
25 Aug - Newspaper ad issued for 22nd AGM notice, record date, and e-voting information. 25 Aug - Newspaper ad issued for 22nd AGM notice, record date, and e-voting information.
5
Shareholders meeting
25 Aug - Postal ballot seeks migration from NSE Emerge to NSE Main Board; e-voting runs 28 Aug-26 Sep 2026. 25 Aug - Postal ballot seeks migration from NSE Emerge to NSE Main Board; e-voting runs 28 Aug-26 Sep 2026.
Frequently Asked Questions about Infinium Pharmachem
What does Infinium Pharmachem Ltd do?
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
Where is Infinium Pharmachem Ltd (INFINIUM) listed?
Infinium Pharmachem Ltd trades as INFINIUM on the NSE.
Which sector does Infinium Pharmachem Ltd belong to?
Infinium Pharmachem Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd has a market capitalisation of ₹405.16 Cr, which places it in the Small Cap band.
What is the PE ratio of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd trades at a PE ratio of 30.10, against a book value of ₹77.68 per share.
What is the 52-week high and low of Infinium Pharmachem Ltd?
Over the last 52 weeks Infinium Pharmachem Ltd has traded between ₹189.4 and ₹285.5.
What is the Return on Equity (ROE) of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd reported a return on equity of 6.28%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INFINIUM.md for Infinium Pharmachem Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.